Our top pick for
This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.
X4 Pharmaceuticals, Inc is a biotechnology business based in the US. X4 Pharmaceuticals shares (XFOR) are listed on the NASDAQ and all prices are listed in US Dollars. X4 Pharmaceuticals employs 68 staff and has a trailing 12-month revenue of around USD$3 million.
|Latest market close||USD$6.92|
|52-week range||USD$5.38 - USD$12.96|
|50-day moving average||USD$6.4211|
|200-day moving average||USD$7.7728|
|Wall St. target price||USD$18.43|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-3.721|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-25)||7.79%|
|1 month (2020-11-04)||7.45%|
|3 months (2020-09-04)||-16.22%|
|6 months (2020-06-04)||-19.44%|
|1 year (2019-12-04)||-32.02%|
|2 years (2018-12-04)||105.34%|
|3 years (2017-12-04)||-57.55%|
|5 years (2015-12-02)||N/A|
Valuing X4 Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of X4 Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
X4 Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, X4 Pharmaceuticals shares trade at around 5x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||USD$3 million|
|Gross profit TTM||USD$0|
|Return on assets TTM||-26.89%|
|Return on equity TTM||-64.65%|
|Market capitalisation||USD$109.9 million|
TTM: trailing 12 months
There are currently 328,171 X4 Pharmaceuticals shares held short by investors – that's known as X4 Pharmaceuticals's "short interest". This figure is 4.9% up from 312,732 last month.
There are a few different ways that this level of interest in shorting X4 Pharmaceuticals shares can be evaluated.
X4 Pharmaceuticals's "short interest ratio" (SIR) is the quantity of X4 Pharmaceuticals shares currently shorted divided by the average quantity of X4 Pharmaceuticals shares traded daily (recently around 72125.494505495). X4 Pharmaceuticals's SIR currently stands at 4.55. In other words for every 100,000 X4 Pharmaceuticals shares traded daily on the market, roughly 4550 shares are currently held short.
However X4 Pharmaceuticals's short interest can also be evaluated against the total number of X4 Pharmaceuticals shares, or, against the total number of tradable X4 Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case X4 Pharmaceuticals's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 X4 Pharmaceuticals shares in existence, roughly 20 shares are currently held short) or 0.0204% of the tradable shares (for every 100,000 tradable X4 Pharmaceuticals shares, roughly 20 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against X4 Pharmaceuticals.
Find out more about how you can short X4 Pharmaceuticals stock.
We're not expecting X4 Pharmaceuticals to pay a dividend over the next 12 months.
X4 Pharmaceuticals's shares were split on a 1:6 basis on 14 March 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your X4 Pharmaceuticals shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for X4 Pharmaceuticals shares which in turn could have impacted X4 Pharmaceuticals's share price.
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for the treatment of primary immune-deficiencies and cancer. Its lead drug candidate is mavorixafor (X4P-001), an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat primary immune-deficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was formerly known as Arsanis, Inc. and changed its name to X4 Pharmaceuticals, Inc. in March 2019. X4 Pharmaceuticals, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing HTZ, with 24-hour and historical pricing before you buy.
Steps to owning and managing HELE, with 24-hour and historical pricing before you buy.
Steps to owning and managing HE, with 24-hour and historical pricing before you buy.
Steps to owning and managing GKOS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYEN, with 24-hour and historical pricing before you buy.
Steps to owning and managing EXAS, with 24-hour and historical pricing before you buy.
Steps to owning and managing EVFM, with 24-hour and historical pricing before you buy.
Steps to owning and managing MRAM, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQNR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SOLO, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.